Impacts of the Kallikrein–Kinin System in Cancer and Its Treatment: A Focus on Drug Delivery and Formulations
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Biologics and Biosimilars".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 52
Special Issue Editors
2. Graduate Program in Environmental Sciences, Community University of Chapecó Region, Efapi, Chapecó 89809-000, SC, Brazil
Interests: kinins; cancer pathophysiology; adverse effects of chemotherapy; cancer pain; anticancer therapy-associated pain; drug delivery
Interests: kinins; cancer pathophysiology; adverse effects of chemotherapy; cancer pain; anticancer therapy-associated pain; drug delivery
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is the second leading cause of death globally, with an incidence of 19.3 million cases in 2020, and these are expected to increase by almost 50% over the next 20 years. Beyond the disease itself, patients also suffer the impacts of the adverse effects of anticancer treatments, such as chemotherapy and hormonal therapy, which include pain and many others. Cancer burden exerts enormous emotional, physical, and financial consequences on individuals and health systems. Thus, it is essential to find strategies that reduce cancer's pathophysiology and its treatment's negative impacts. The kallikrein–kinin system has been widely studied in the pathogenesis of various types of cancer. Kinins exercise regulatory control over tumor proliferation, survival, and invasion by acting in cancer cells and tumor microenvironment cells. This system also underlies the adverse effects of anticancer therapy. A target capable of treating both the pathophysiology of cancer and alleviating the negative impacts of anticancer therapy would be valuable for disease control and treatment adherence. The kallikrein–kinin system may be interesting in this sense. The development of innovative drug delivery systems and formulations targeting the kallikrein–kinin system could provide more effective and safer therapeutic options for cancer patients, potentially improving treatment outcomes and quality of life.
This Special Issue aims to collate articles that address the role of the kallikrein–kinin system in cancer pathophysiology and the adverse effects of anticancer therapy. We particularly welcome submissions that explore the potential of novel drug delivery approaches and formulations targeting the kallikrein–kinin system, as well as their preclinical and clinical applications in cancer treatment.
In this Special Issue, original research articles and reviews are welcome to be submitted. Research areas may include, but are not limited to, the following:
- Kallikrein–kinin system in cancer pathophysiology;
- Kallikrein–kinin system in cancer pain;
- Kallikrein–kinin system in the adverse effects of anticancer therapy;
- Kallikrein–kinin systems in anticancer therapy-associated pain;
- Kallikrein–kinin system-targeted drug delivery systems;
- Kallikrein–kinin system-targeted formulations;
- Nanoparticle-based delivery systems for kallikrein–kinin system modulators;
- Liposomal formulations targeting the kallikrein–kinin system;
- Polymeric micelles for kallikrein–kinin system-targeted drug delivery;
- Prodrug strategies for kallikrein–kinin system modulation.
Dr. Indiara Brusco
Dr. Sara Marchesan De Oliveira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer pathophysiology
- cancer pain
- adverse effects of chemotherapy
- cancer-related pain mechanisms
- tumor microenvironment
- kininogens
- kininases
- kinin B1 and B2 receptors
- anticancer treatment
- kinin B1 and B2 receptor antagonists
- drug delivery
- drug formulations
- nanoparticles
- liposomes
- polymeric micelles
- prodrugs
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
